Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection

E. Dadachova, T. Burns, R. A. Bryan, C. Apostolidis, M. W. Brechbiel, Joshua D. Nosanchuk, A. Casadevall, Liise-anne Pirofski

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Streptococcus pneumoniae is an important cause of community-acquired pneumonia, meningitis, and bacteremia. The problem of pneumococcal disease is exacerbated by increasing drug resistance. Furthermore, patients with impaired immunity are at high risk for invasive pneumococcal infections. Thus, there is an urgent need for new approaches to antimicrobial therapy. Antibody therapies take advantage of the specificity and high affinity of the antigen-antibody interaction to deliver antibacterial compounds to a site of infection in the form of naked or conjugated antibodies. We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice. In the present study, we investigated the feasibility of applying a RIT approach to the treatment of S. pneumoniae infection by evaluating the susceptibility of S. pneumoniae to radiolabeled antibody in vitro and in an animal infection model. For the specific antibody carrier, we used human monoclonal antibody Dll, which binds to pneumococcal capsular polysaccharide 8. We have selected the alpha particle emitter 213Bi as the radionuclide for conjugation to the antibody. Incubation of serotype 8 S. pneumoniae with 213 Bi-D11 resulted in dose-dependent killing of bacteria. RIT of S. pneumoniae infection in C57BL/6 mice showed that 60% more mice survived in the 213 Bi-D11-treated group (80 μCi) than in the untreated group (P < 0.01). The treatment did not cause hematological toxicity, as demonstrated by platelet counts. This feasibility study establishes that RIT can be applied to the treatment of bacterial infections.

Original languageEnglish (US)
Pages (from-to)1624-1629
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Radioimmunotherapy
Pneumococcal Infections
Streptococcus pneumoniae
Antibodies
Alpha Particles
Therapeutics
Antibody Affinity
Mycoses
Feasibility Studies
Bacteremia
Infection
Platelet Count
Inbred C57BL Mouse
Meningitis
Bacterial Infections
Drug Resistance
Radioisotopes
Polysaccharides
Immunity
Pneumonia

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection. / Dadachova, E.; Burns, T.; Bryan, R. A.; Apostolidis, C.; Brechbiel, M. W.; Nosanchuk, Joshua D.; Casadevall, A.; Pirofski, Liise-anne.

In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 5, 05.2004, p. 1624-1629.

Research output: Contribution to journalArticle

Dadachova, E. ; Burns, T. ; Bryan, R. A. ; Apostolidis, C. ; Brechbiel, M. W. ; Nosanchuk, Joshua D. ; Casadevall, A. ; Pirofski, Liise-anne. / Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 5. pp. 1624-1629.
@article{f005bd08aa4b48cb902ccc21f67db62a,
title = "Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection",
abstract = "Streptococcus pneumoniae is an important cause of community-acquired pneumonia, meningitis, and bacteremia. The problem of pneumococcal disease is exacerbated by increasing drug resistance. Furthermore, patients with impaired immunity are at high risk for invasive pneumococcal infections. Thus, there is an urgent need for new approaches to antimicrobial therapy. Antibody therapies take advantage of the specificity and high affinity of the antigen-antibody interaction to deliver antibacterial compounds to a site of infection in the form of naked or conjugated antibodies. We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice. In the present study, we investigated the feasibility of applying a RIT approach to the treatment of S. pneumoniae infection by evaluating the susceptibility of S. pneumoniae to radiolabeled antibody in vitro and in an animal infection model. For the specific antibody carrier, we used human monoclonal antibody Dll, which binds to pneumococcal capsular polysaccharide 8. We have selected the alpha particle emitter 213Bi as the radionuclide for conjugation to the antibody. Incubation of serotype 8 S. pneumoniae with 213 Bi-D11 resulted in dose-dependent killing of bacteria. RIT of S. pneumoniae infection in C57BL/6 mice showed that 60{\%} more mice survived in the 213 Bi-D11-treated group (80 μCi) than in the untreated group (P < 0.01). The treatment did not cause hematological toxicity, as demonstrated by platelet counts. This feasibility study establishes that RIT can be applied to the treatment of bacterial infections.",
author = "E. Dadachova and T. Burns and Bryan, {R. A.} and C. Apostolidis and Brechbiel, {M. W.} and Nosanchuk, {Joshua D.} and A. Casadevall and Liise-anne Pirofski",
year = "2004",
month = "5",
doi = "10.1128/AAC.48.5.1624-1629.2004",
language = "English (US)",
volume = "48",
pages = "1624--1629",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection

AU - Dadachova, E.

AU - Burns, T.

AU - Bryan, R. A.

AU - Apostolidis, C.

AU - Brechbiel, M. W.

AU - Nosanchuk, Joshua D.

AU - Casadevall, A.

AU - Pirofski, Liise-anne

PY - 2004/5

Y1 - 2004/5

N2 - Streptococcus pneumoniae is an important cause of community-acquired pneumonia, meningitis, and bacteremia. The problem of pneumococcal disease is exacerbated by increasing drug resistance. Furthermore, patients with impaired immunity are at high risk for invasive pneumococcal infections. Thus, there is an urgent need for new approaches to antimicrobial therapy. Antibody therapies take advantage of the specificity and high affinity of the antigen-antibody interaction to deliver antibacterial compounds to a site of infection in the form of naked or conjugated antibodies. We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice. In the present study, we investigated the feasibility of applying a RIT approach to the treatment of S. pneumoniae infection by evaluating the susceptibility of S. pneumoniae to radiolabeled antibody in vitro and in an animal infection model. For the specific antibody carrier, we used human monoclonal antibody Dll, which binds to pneumococcal capsular polysaccharide 8. We have selected the alpha particle emitter 213Bi as the radionuclide for conjugation to the antibody. Incubation of serotype 8 S. pneumoniae with 213 Bi-D11 resulted in dose-dependent killing of bacteria. RIT of S. pneumoniae infection in C57BL/6 mice showed that 60% more mice survived in the 213 Bi-D11-treated group (80 μCi) than in the untreated group (P < 0.01). The treatment did not cause hematological toxicity, as demonstrated by platelet counts. This feasibility study establishes that RIT can be applied to the treatment of bacterial infections.

AB - Streptococcus pneumoniae is an important cause of community-acquired pneumonia, meningitis, and bacteremia. The problem of pneumococcal disease is exacerbated by increasing drug resistance. Furthermore, patients with impaired immunity are at high risk for invasive pneumococcal infections. Thus, there is an urgent need for new approaches to antimicrobial therapy. Antibody therapies take advantage of the specificity and high affinity of the antigen-antibody interaction to deliver antibacterial compounds to a site of infection in the form of naked or conjugated antibodies. We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice. In the present study, we investigated the feasibility of applying a RIT approach to the treatment of S. pneumoniae infection by evaluating the susceptibility of S. pneumoniae to radiolabeled antibody in vitro and in an animal infection model. For the specific antibody carrier, we used human monoclonal antibody Dll, which binds to pneumococcal capsular polysaccharide 8. We have selected the alpha particle emitter 213Bi as the radionuclide for conjugation to the antibody. Incubation of serotype 8 S. pneumoniae with 213 Bi-D11 resulted in dose-dependent killing of bacteria. RIT of S. pneumoniae infection in C57BL/6 mice showed that 60% more mice survived in the 213 Bi-D11-treated group (80 μCi) than in the untreated group (P < 0.01). The treatment did not cause hematological toxicity, as demonstrated by platelet counts. This feasibility study establishes that RIT can be applied to the treatment of bacterial infections.

UR - http://www.scopus.com/inward/record.url?scp=2142812932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142812932&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.5.1624-1629.2004

DO - 10.1128/AAC.48.5.1624-1629.2004

M3 - Article

VL - 48

SP - 1624

EP - 1629

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -